The renal parenchyma evaluation: MAG3 vs. DMSA.

Area of Science:

• Nuclear Medicine
• Radiology
• Nephrology

Background:

• Tc-99m dimercaptosuccinic acid (DMSA) scintigraphy is the gold standard for evaluating renal parenchymal lesions and differential kidney function.
• Dynamic renal scintigraphy using Tc-99m mercaptoacetyltriglycine (MAG3) is primarily used for assessing ren al drainage.

Purpose of the Study:

• To evaluate the efficacy of Tc-99m mercaptoacetyltriglycine (MAG3) dynamic renal scintigraphy in assessing parenchymal lesions and differential kidney function.
• To compare the diagnostic accuracy of MAG3 scintigraphy with the reference standard DMSA scintigraphy for these purposes.

Main Methods:

• A comparative study involving 188 patients who underwent both DMSA and MAG3 scintigraphy within three months.
• Group 1 (N=83): DMSA images were compared with the parenchymal phase of MAG3 scintigraphy for morphological assessment by four independent observers.
• Group 2 (N=105): Differential kidney function was calculated from both DMSA and MAG3 studies and compared.

Main Results:

• Complete concordance in findings between DMSA and MAG3 imaging was observed in 85% of patients.
• No statistically significant differences were found in the calculated differential kidney function between DMSA and MAG3 studies.
• The study demonstrated that most parenchymal lesions identified on DMSA scans were also detectable on the parenchymal phase of MAG3 scans.

Conclusions:

• Tc-99m mercaptoacetyltriglycine (MAG3) dynamic renal scintigraphy is a viable alternative to DMSA scintigraphy for assessing renal parenchymal lesions.
• Both DMSA and MAG3 scintigraphy can be utilized interchangeably for the accurate calculation of differential kidney function.
• MAG3 scintigraphy offers a comprehensive evaluation of both renal morphology and function, similar to DMSA.